

Department of Defense Pharmacoeconomic Center

1750 Greeley Rd., Bldg. 4011, Rm. 217
Fort Sam Houston, TX 78234-6190

MCCS-GPE

26 January 2000

MEMORANDUM FOR Assistant Secretary of Defense (Health Affairs)

SUBJECT: Minutes of an Interim Meeting of the Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee—Program Budget Decision (PBD) No. 041

1. In accordance with Health Affairs policy 98-025, an interim meeting of the DoD P&T Committee convened via teleconference at 1200 on 26 January 2000. The purpose of this meeting was to identify additions to the Basic Core Formulary (BCF) in response to additional funding for military pharmacies provided by the Program Budget Decision (PBD) No. 041.

2. MEMBERS Participating in the Teleconference:

COL Daniel D. Remund, MS	Co-chairman
CDR Terrance Eglund, MC	Co-chairman
COL Rosa Stith, MC	Army
LTC Judith O'Connor, MC	Army
Danielle Doyle	Army
LCDR Kevin Cook, MSC	Navy
COL (select) John R. Downs, MC	Air Force
MAJ George Jones, BSC	Air Force
CDR Robert W. Rist	Coast Guard

COL Daniel D. Remund voted as proxy for CDR Matt Nutaitis.

COL (select) Bill Sykora was absent.

3. OTHERS Participating in the Teleconference:

COL W. Mike Heath	Pharmacy Consultant, USA
COL Ardis Meier	Associate Chief, BSC for Pharmacy, USAF
CAPT Greg Hall	Director, Pharmacy Department, Portsmouth Naval Hospital

4. NEW BUSINESS

A. The TRICARE Management Activity (TMA) and the DoD Pharmacy Board of Directors determined that funds allocated to MTF pharmacies through PBD No. 041 should be used to increase and standardize the availability of drugs at MTF pharmacies. The DoD Pharmacoeconomic Center (PEC) developed a set of recommended changes and additions to the BCF for the DoD P&T Committee to consider.

B. The Committee added the following drugs to the BCF:

1. Metformin
2. Tamoxifen
3. Alendronate
4. Citalopram
5. Fluoxetine
6. Paroxetine
7. Sertraline
8. Sumatriptan autoinjector

C. The Committee decided to modify the BCF as follows:

1. The BCF will specify that MTFs must have at least one low molecular weight heparin/heparinoid (aldeparin, dalteparin, danaparoid, enoxaparin) on the MTF formulary. The MTF decides which low molecular weight heparin/heparinoid(s) to have on the MTF formulary.
2. The BCF will specify that MTFs must have at least one leukotriene antagonist (monelukast, zafirlukast, zileuton) on the MTF formulary. The MTF decides which leukotriene antagonist(s) to have on the MTF formulary.
3. The BCF will specify that MTFs must have at least one second-generation antihistamine (cetirizine, fexofenadine, loratadine) on the MTF formulary. The MTF decides which second generation antihistamine(s) to have on the MTF formulary.
4. The BCF will specify that MTFs must have at least one oral triptan (naratriptan, rizatriptan, sumatriptan, zolmitriptan) on the MTF formulary. The MTF decides which oral triptan to have on the MTF formulary.

D. The Committee decided not to add gabapentin to the BCF.

E. The Committee stressed that the changes and additions to the BCF are dependent on the PBD funds actually being used to support MTF pharmacy pharmaceutical purchases.

5. ADJOURNMENT: The meeting adjourned at 1400 hours. The committee immediately reconvened to determine which drugs should be covered by Advances in Medical Practice (AMP) funding.

<signed>
DANIEL D. REMUND
COL, MS, USA
Co-chairman

<signed>
TERRANCE EGLAND
CDR, MC, USN
Co-chairman